A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab.

Authors :: Saito, Naoto
Hatanaka, Takeshi
Nakano, Sachi
Hazama, Yoichi
Yoshida, Sachiko
Hachisu, Yoko
Tanaka, Yoshiki
Yoshinaga, Teruo
Kashiwabara, Kenji
Kubo, Norio
Hosouchi, Yasuo
Tojima, Hiroki
Kakizaki, Satoru
Uraoka, Toshio
Source :: Clinical Case Reports. Jul2022, Vol. 10 Issue 7, p1-8. 8p.
Publication Year :: 2022
Abstract: An 81‐year‐old man initially underwent right hepatic lobectomy for liver cancer and was pathologically diagnosed with combined hepatocellular and cholangiocarcinoma (CHC). At 13 months after resection, multiple lymph node metastases were observed. We started atezolizumab plus bevacizumab (Atez/Bev), achieving a 7.5‐month progression‐free survival. Atez/Bev might exhibit efficacy for CHC patients. [ABSTRACT FROM AUTHOR]

Subjects :: *BEVACIZUMAB
*ATEZOLIZUMAB
*CHOLANGIOCARCINOMA
*LIVER cancer
*LYMPHATIC metastasis

Full Text Access

Tools